Skip to main content
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2000 Sep;77(3):306–330. doi: 10.1007/BF02386743

Syringe availability as HIV prevention: A review of modalities

Phillip Coffin 1
PMCID: PMC3456039  PMID: 10976607

Abstract

This review examines recent research into modalities for improving access to sterile syringes for injection drug users (IDUs) as a means to reduce human immunodeficiency virus (HIV) transmission. English language studies with empirical data were collected through Uncover reports and MedLine searches from 1998 to 2000. Although syringe-exchange programs are the most established and well-evaluated means of improving access to sterile syringes, research on alternative modalities—such as pharmacy sale, injector-specific packs, mass distribution, and vending machines—and on coverage of special populations suggests the need to pursue multiple avenues of increasing syringe availability simultaneously and, in particular, to explore modalities other than syringe-exchange programs when HIV incidence is under control. The impacts on HIV transmission of cocaine injection and sex with IDUs need to be explored further. Finally, any evidence of declining hepatitis C incidence among young IDUs might serve as a surrogate for a sharp drop in injection-related HIV risk behaviors in that population.

Full Text

The Full Text of this article is available as a PDF (1.4 MB).

Footnotes

Mr. Coffin was a research associated at The Lindesmith Center during the preparation of this paper.

References

  • 1.HIV/AIDS Surveillance Report. Atlanta, GA: Centers for Disease Control and Prevention; 1999. pp. 12–12. [Google Scholar]
  • 2.Centers for Disease Control and Prevention Publication of HIV-prevention bulletin for health-care providers regarding advice to persons who inject illicit drugs. MMWR Morb Mortal Wkly Rep. 1997;46:510–510. [Google Scholar]
  • 3.Anderson JE, MacGowan R, Jones TS, Parker P. Needle hygiene and sources of needles for injection drug users: data from a national survey. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S147–S148. doi: 10.1097/00042560-199802001-00030. [DOI] [PubMed] [Google Scholar]
  • 4.HIV/AIDS and Related Diseases in Australia: Annual Surveillance Report, 1998. Sydney, Australia: University of New South Wales; 1998. [Google Scholar]
  • 5.Stimson GV, Keene J, Parry-Langdon N. Evaluation of the Syringe Exchange Programme Wales, 1990–91. London: The Centre for Research on Drugs and Health Behavior, University of London; 1991. [Google Scholar]
  • 6.Lurie P, Reingold A. The Public Health Impact of Needle Exchange Programs in the United States and Abroad. Berkeley, CA: University of California, School of Public Health; San Francisco, CA: University of California, Institute for Health Policy Studies; 1993. [Google Scholar]
  • 7.Normand J, Vlahov D, Moses LE. Preventing HIV Transmission: the Role of Sterile Needles and Bleach. Washington, DC: National Academy of Medicine; 1995. [PubMed] [Google Scholar]
  • 8.Buning EC. Effects of Amsterdam needle and syringe exchange. Int J Addict. 1991;26:1303–1311. doi: 10.3109/10826089109062162. [DOI] [PubMed] [Google Scholar]
  • 9.Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997;349:1797–1800. doi: 10.1016/S0140-6736(96)11380-5. [DOI] [PubMed] [Google Scholar]
  • 10.MacDonald M, Wodak AD, Ali R, et al. HIV prevalence and risk behavior in needle exchange attenders: a national study. Med J Aust. 1997;166:237–240. [PubMed] [Google Scholar]
  • 11.Heimer R, Khoshnood K, Bigg D. Syringe use and reuse: effects of syringe exchange programs in four cities. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S37–S44. doi: 10.1097/00042560-199802001-00008. [DOI] [PubMed] [Google Scholar]
  • 12.Broadhead RS, Hulst Y, Hechathorn DD. Termination of an established needle-exchange: a study of claims and their impact. Soc Probl. 1999;46:48–66. [Google Scholar]
  • 13.Ljungberg B, Christensson B, Tunving K, et al. HIV prevention among injecting drug users: three years of experience from a syringe exchange program in Sweden. J AIDS. 1991;4:890–895. [PubMed] [Google Scholar]
  • 14.Multi-centre study on drug injecting and risk of HIV infection. Geneva, Switzerland: WHO; 1993. [Google Scholar]
  • 15.Dolan KA, Stimson GV, Donoghoe MC. Reductions in HIV risk behaviours and stable HIV prevalence in cohorts of syringe-exchange clients and other injectors in England. Drug Alcohol Rev. 1993;12:133–142. doi: 10.1080/09595239300185561. [DOI] [PubMed] [Google Scholar]
  • 16.Stimson GV. Harm reduction in action: putting theory into practice. Int J Drug Policy. 1998;9:401–409. doi: 10.1016/S0955-3959(98)00056-5. [DOI] [Google Scholar]
  • 17.Peak A, Rana S, Maharjan SH, Jolley D, Crofts N. Declining risk for HIV among injecting drug users in Kathmandu, Nepal: the impact of a harm-reduction programme. AIDS. 1995;9:1067–1070. doi: 10.1097/00002030-199509000-00013. [DOI] [PubMed] [Google Scholar]
  • 18.Ameijden EJ, Hoek JA, Mientjes GH, Coutinho RA. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol. 1993;9:255–262. doi: 10.1007/BF00146260. [DOI] [PubMed] [Google Scholar]
  • 19.Hagan H, Jarlais DC, Friedman SR, Purchase D. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274:1226–1231. doi: 10.1001/jama.274.15.1226. [DOI] [PubMed] [Google Scholar]
  • 20.Oliver K. HIV seroincidence in Portland, OR. In:Proceedings of the Annual National North American Syringe Exchange Conference; February 24–27, 1993; Boston, MA.
  • 21.Haastrecht HJ, Hoek JA, Bardoux C, Leentvaar-Kuypers A, Coutinho RA. The course of the HIV epidemic among intravenous drug users in Amsterdam, The Netherlands. Am J Public Health. 1991;81:59–62. doi: 10.2105/ajph.81.1.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kaplan EH, Hemer R. HIV incidence among needle exchange participants: estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol. 1994;7:182–189. [PubMed] [Google Scholar]
  • 23.Kaplan EH, Khoshnood K, Heimer R. A decline in HIV-infected needles returned to New Haven's needle exchange program: client shift or needle exchange? Am J Public Health. 1994;84:1991–1994. doi: 10.2105/ajph.84.12.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ameijden EJ, Hoek JA, Haastrecht HJ, Coutinho RA. The harm reduction approach and risk factors for human immunodeficiency virus (HIV) seroconversion injecting drug users, Amsterdam. Am J Epidemiol. 1992;136:236–243. doi: 10.1093/oxfordjournals.aje.a116489. [DOI] [PubMed] [Google Scholar]
  • 25.O'Brien M. Seroincidence among injecting drug users in the Chicago Syringe Exchange. In:Proceedings of the Annual North American Syringe Exchange Conference; April 27–30, 1994; Santa Cruz, CA.
  • 26.Paone D, des Jarlais DC, Caloir S, et al. New York City syringe exchange: expansion, risk reduction, and seroincidence. In:Proceedings of the 10th International Conference on AIDS; August 7–12, 1994; Yokohama, Japan.
  • 27.Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996;348:987–991. doi: 10.1016/S0140-6736(96)02536-6. [DOI] [PubMed] [Google Scholar]
  • 28.Kaplan EH, Heimer R. What happened to HIV transmission among drug injectors in New Haven? Chance: New Directions for Statistics and Computing. 1993;6:9–14. [Google Scholar]
  • 29.Hankins C, Gendron S, Tran T. Montreal needle exchange attenders versus non-attenders: what's the difference? In:Proceedings of the 10th International Conference on AIDS; August 7–12, 1994; Yokohama, Japan.
  • 30.Bruneau J, Lamothe F, Franco E, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol. 1997;146:994–1002. doi: 10.1093/oxfordjournals.aje.a009240. [DOI] [PubMed] [Google Scholar]
  • 31.Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11:F59–F65. doi: 10.1097/00002030-199708000-00001. [DOI] [PubMed] [Google Scholar]
  • 32.Heimer R, Kaplan EH, Khoshnood K. Needle exchange decreases the prevalence of HIV-1 proviral DNA in returned syringes in New Haven, Connecticut. Am J Med. 1993;95:214–220. doi: 10.1016/0002-9343(93)90263-O. [DOI] [PubMed] [Google Scholar]
  • 33.Kaplan EH. Probability models of needle exchange. Operations Res. 1995;43:558–569. [Google Scholar]
  • 34.Ameijden E, Coutinho R. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS. 1998;12:625–634. doi: 10.1097/00002030-199806000-00012. [DOI] [PubMed] [Google Scholar]
  • 35.Bruneau J, Franco E, Lamothe F. Assessing harm reduction strategies: the dilemma of observational studies. Am J Epidemiol. 1997;146:1004–1008. [Google Scholar]
  • 36.Friedman SR, Neaigus A, Jose B, et al. Sociometric risk networks and HIV risk. Am J Public Health. 1997;87:1289–1296. doi: 10.2105/ajph.87.8.1289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Garfein RS, Lyerla R, Jones TS, Nakashima AK, Monterroso ER, Vlahov D. Re: “High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study”. Am J Epidemiol. 1999;150:325–325. doi: 10.1093/oxfordjournals.aje.a010009. [DOI] [PubMed] [Google Scholar]
  • 38.Bruneau J, Lachance N, Lamothe F, Vinelette J. HIV seroconversion among injection drug users attending needle exchange programs in Montreal, Quebec, Canada: before and after 1995 [abstract]. In:Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections; January–February 2000; San Francisco, CA. Abstract 484.
  • 39.Schechter MT, Strathdee SA, Cornelisse PGA, et al. Do needle exchange programmes increase the spread of HIV among injection drug users? An investigation of the Vancouver outbreak. AIDS. 1999;13:F45–F51. doi: 10.1097/00002030-199904160-00002. [DOI] [PubMed] [Google Scholar]
  • 40.Paone D, Jarlais DC, Caloir S, Jose B, Shi Q, Friedman SR. Continued risky injection subsequent to syringe exchange use among injection drug users in New York City. AIDS Educ Prev. 1997;9:505–510. [PubMed] [Google Scholar]
  • 41.The Twin Epidemics of Substance Use and HIV. Washington, DC: National Commission on Acquired Immune Deficiency Syndrome; 1991. [Google Scholar]
  • 42.Needle Exchange Programs: Research Suggests Promise as an AIDS Prevention Strategy. Washington, DC: US Government Printing Office; 1999. [Google Scholar]
  • 43.The Effectiveness of AIDS Prevention Efforts. Washington, DC: US Government Printing Office; 1995. [Google Scholar]
  • 44.Proceedings of the National Institute of Health Consensus Conference; February 11–13, 1997; Bethesda, MD.
  • 45.Report to the Committee on Appropriations for the Department of Labor, Health and Human Services and Related Agencies. Washington, DC: US Department of Health and Human Services; 1998. [Google Scholar]
  • 46.Paone D, Cooper H, Alperen J, Shi Q, Jarlais DC. HIV risk behaviors of current sex workers attending syringe exchange: the experiences of women in five US cities. AIDS Care. 1999;11:269–280. doi: 10.1080/09540129947910. [DOI] [PubMed] [Google Scholar]
  • 47.Jürgens R, Riley D. Responding to AIDS and drug use in prisons in Canada. Int J Drug Policy. 1997;8:31–39. [Google Scholar]
  • 48.Bird AG, Gore SM, Hutchinson SJ, Lewis SC, Cameron S, Burns S. Harm reduction measures and injecting inside prison versus mandatory drugs testing: results of a cross sectional anonymous questionnaire survey. BMJ. 1997;315:21–24. doi: 10.1136/bmj.315.7099.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Rapid Assessment and Response to Injecting Drug Use at Shymkent, South Kazakstan, Almaty. Geneva, Switzerland: UNAIDS; 1998. [Google Scholar]
  • 50.Nelles J. The contradictory position of HIV-prevention in prison: Swiss experiences. Int J Drug Policy. 1997;1:2–4. [Google Scholar]
  • 51.Jürgens R. Promoting the rights of prisoners: condoms, bleach, needles, methadone and care in prisons. In:Proceedings of the International Conference on the Reduction of Drug-Related Harm; March 21–25, 1998; Geneva, Switzerland. Abstract 44191.
  • 52.Crofts N, Webb-Pullman J, Dolan K. An Analysis of Trends over Time in Social and Behavioural Factors Related to the Transmission of HIV Among Injecting Drug Users and Prison Inmates. Canberra, Australia: AGPS; 1996. [Google Scholar]
  • 53.Nelles J, Fuhrer A, Hirsbrunner H, Harding T. Provision of syringes: the cutting edge of harm reduction in prison? BMJ. 1998;317:270–273. doi: 10.1136/bmj.317.7153.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Dehne KL, Khodakevich L, Hamers FF, Schwartlander B. The HIV/AIDS epidemic in eastern Europe: recent patterns and trends and their implications for policy-making. AIDS. 1999;13:741–749. doi: 10.1097/00002030-199905070-00002. [DOI] [PubMed] [Google Scholar]
  • 55.Rhodes T, Stimson GV, Crofts N, et al. Drug injecting, rapid HIV spread, and the “risk environment” implications for assessments and response.AIDS. 2000. In press. [PubMed]
  • 56.Prevalence of Injecting Drug Use and HIV Infection in Tashkent: Report on Conduct of Rapid Assessment and Response. Geneva, Switzerland: UNAIDS; 1998. [Google Scholar]
  • 57.Boston Globe Online. Russian HIV cases surge, more than 30,000 infected. Available on-line at: www.boston.com/globe. Accessed March 2, 2000.
  • 58.Kalichman SC, Kelly JA, Sikkema KJ, Koslov AP, Shaboltas A, Granskaya J. The emerging AIDS crisis in Russia: review of enabling factors and prevention needs. Int J STD AIDS. 2000;11(2):71–75. doi: 10.1258/0956462001915345. [DOI] [PubMed] [Google Scholar]
  • 59.Heimer R. Do homebrewed liquid opiates transmit HIV-1? In: Proceedings of the Sixth International Conference on AIDS, STDs and Cancer; May 23–28, 1999; St. Petersburg, Russia.
  • 60.Heimer R, Abdala N, Goldsamt LA, et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;22:194–199. doi: 10.1097/00126334-199910010-00013. [DOI] [PubMed] [Google Scholar]
  • 61.Rhodes T, Stimson GV, Fitch C, Ball A, Renton A. Rapid assessment, injecting drug use, and public health. Lancet. 1999;354:65–68. doi: 10.1016/S0140-6736(98)07612-0. [DOI] [PubMed] [Google Scholar]
  • 62.Gray J. Operating needle exchange programs in the hills of Thailand. AIDS Care. 1995;7:489–499. doi: 10.1080/09540129550126434. [DOI] [PubMed] [Google Scholar]
  • 63.Sarkar S, Mookerjee P, Roy AE. Descriptive epidemiology of intravenous heroin users: a new risk group for transmission of HIV in India. J Infect. 1991;23:201–207. doi: 10.1016/0163-4453(91)92364-B. [DOI] [PubMed] [Google Scholar]
  • 64.Ismail R. HIV/AIDS in Malaysia. AIDS. 1998;12:S1–S10. [Google Scholar]
  • 65.Friedman SR, Jarlais DC, Neaigus A, et al. AIDS and the new drug injector. Nature. 1989;339:333–334. doi: 10.1038/339333a0. [DOI] [PubMed] [Google Scholar]
  • 66.Singh M. Harm reduction and street-based program: looking into Nepal. Subst Use Misuse. 1998;33:1069–1074. doi: 10.3109/10826089809062207. [DOI] [PubMed] [Google Scholar]
  • 67.Quan VM, Chung A, Abdul-Quader AS. The feasibility of a syringe-needle-exchange program in Vietnam. Subst Use Misuse. 1998;33:1055–1067. doi: 10.3109/10826089809062206. [DOI] [PubMed] [Google Scholar]
  • 68.Riehman KS. Injecting Drug Use and AIDS in Developing Countries: Determinants and Issues for Policy Consideration. Geneva, Switzerland: World Bank, Policy Research and Development; 1996. [Google Scholar]
  • 69.Maharjan SH, Singh M. Street based AIDS outreach program for injecting drug users (IDUs). In:Proceedings of the 11th International Conference on AIDS; July 7–12, 1996; Vancouver, Canada. Abstract Mo.D.243.
  • 70.Chatterjee A, Hangzo CZ, Abdul-Quader AS, et al. Evidence of effectiveness of street based peer outreach. In:Proceedings of the 11th International Conference on AIDS; July 7–12, 1996; Vancouver, Canada. Abstract Th.C.422.
  • 71.Choopanya K, Vanichseni KS, Jarlais DC, et al. Risk factors and HIV seropositivity among injecting drug users in Bangkok. AIDS. 1991;5:1509–1513. doi: 10.1097/00002030-199112000-00014. [DOI] [PubMed] [Google Scholar]
  • 72.Jarlais DC, Choopanya K, Vanichseni S, et al. AIDS risk reduction and reduced HIV seroconversion among injection drug users in Bangkok. Am J Public Health. 1994;84:452–455. doi: 10.2105/ajph.84.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in shortterm injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655–661. doi: 10.2105/ajph.86.5.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Kipke MD, O'Connor S, Palmer R, MacKenzie RG. Street youth in Los Angeles: profile of a group at high risk for human immunodeficiency virus infection. Arch Pediatr Adolesc Med. 1995;149:513–519. doi: 10.1001/archpedi.1995.02170180043006. [DOI] [PubMed] [Google Scholar]
  • 75.Kleinman PH, Goldsmith DS, Friedman SR, Hopkins W, Jarlais DC. Knowledge about and behaviors affecting the spread of AIDS: a street survey of intravenous drug users and their associates in New York City. Int J Addict. 1990;25:345–361. doi: 10.3109/10826089009053164. [DOI] [PubMed] [Google Scholar]
  • 76.Kipke MD, Unger JB, Palmer R. Drug-injecting street youth: a comparison of HIV-risk injection behaviors between needle exchange users and nonusers. AIDS Behav. 1997;1:225–232. [Google Scholar]
  • 77.Weiker RL, Edgington R, Kipke MD. A collaborative evaluation of a needle exchange program for youth. Health Educ Behav. 1999;26:213–224. doi: 10.1177/109019819902600205. [DOI] [PubMed] [Google Scholar]
  • 78.Wyld R, Robertson JR, Brettle RP, Mellor J, Prescott L, Simmonds P. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J Infect Dis. 1997;35:163–166. doi: 10.1016/s0163-4453(97)91677-7. [DOI] [PubMed] [Google Scholar]
  • 79.Hoek JA, Haastrecht HJ, Goudsmit J, Wolf F, Coutinho RA. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis. 1990;162:823–826. doi: 10.1093/infdis/162.4.823. [DOI] [PubMed] [Google Scholar]
  • 80.Beek I, Buckley R, Stewart M, MacDonald M, Kaldor J. Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourinary Med. 1994;70:321–324. doi: 10.1136/sti.70.5.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Crofts N, Jolley D, Kaldor J, Beek I, Wodak A. The epidemiology of HCV infection among injecting drug users in Australia. J Epidemiol Community Health. 1997;51:692–697. doi: 10.1136/jech.51.6.692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 1998;317:433–437. doi: 10.1136/bmj.317.7156.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Patz JA, Jodrey D. Occupational health in surgery: risks extend beyond the operating room. Aust N Z J Surg. 1995;65:627–629. doi: 10.1111/j.1445-2197.1995.tb00667.x. [DOI] [PubMed] [Google Scholar]
  • 84.Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990–1995. Med J Aust. 1997;167:17–20. doi: 10.5694/j.1326-5377.1997.tb138757.x. [DOI] [PubMed] [Google Scholar]
  • 85.Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S11–S19. doi: 10.1097/00042560-199802001-00004. [DOI] [PubMed] [Google Scholar]
  • 86.Hagan H, Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995;85:1531–1537. doi: 10.2105/ajph.85.11.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149:203–213. doi: 10.1093/oxfordjournals.aje.a009792. [DOI] [PubMed] [Google Scholar]
  • 88.Levine OS, Vlahov D, Brookmeyer R, Cohn S, Nelson KE. Differences in the incidence of hepatitis B and human immunodeficiency virus infections among injecting drug users. J Infect Dis. 1996;173:579–583. doi: 10.1093/infdis/173.3.579. [DOI] [PubMed] [Google Scholar]
  • 89.Lurie P, Jones ST, Foley J. A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S45–S51. doi: 10.1097/00042560-199802001-00009. [DOI] [PubMed] [Google Scholar]
  • 90.Nelson KE, Vlahov D, Cohn S, Lindsay A, Solomon L, Anthony JC. Human immunodeficiency virus infection in diabetic intravenous drug users. JAMA. 1991;266:2259–2261. doi: 10.1001/jama.266.16.2259. [DOI] [PubMed] [Google Scholar]
  • 91.Gostin LO. The legal environment impeding access to sterile syringes and needles: the conflict between law enforcement and public health. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S60–S70. doi: 10.1097/00042560-199802001-00012. [DOI] [PubMed] [Google Scholar]
  • 92.Morse LJ. Deregulation of syringes and needles for medical use and to prevent the spread of blood-borne pathogens among illicit injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S143–S144. doi: 10.1097/00042560-199802001-00026. [DOI] [PubMed] [Google Scholar]
  • 93.Case P, Meehan T, Jones ST. Arrests and incarceration of injection drug users for syringe possession in Massachusetts: implications for HIV prevention. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S71–S75. doi: 10.1097/00042560-199802001-00013. [DOI] [PubMed] [Google Scholar]
  • 94.Wright LN, Gebbie KM. Oregon's exclusion of syringes from its 1987 drug paraphernalia law was an HIV prevention measure. J. Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S144–S155. doi: 10.1097/00042560-199802001-00027. [DOI] [PubMed] [Google Scholar]
  • 95.Gleghorn AA, Jones TS, Doherty MC, Celentano DD, Vlahov D. Acquisition and use of needles and syringes by injecting drug users in Baltimore, Maryland. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:97–103. [PubMed] [Google Scholar]
  • 96.Rich JD, Dickinson BP, Liu KL, et al. Strict syringe laws in Rhode Island are associated with high rates of reusing syringes and HIV risks among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S140–S141. doi: 10.1097/00042560-199802001-00024. [DOI] [PubMed] [Google Scholar]
  • 97.AIDS Surveillance Data, Maine. Augusta, Maine: Maine Bureau of Health; 1996. [Google Scholar]
  • 98.Viral Hepatitis Surveillance Data, Maine. Augusta, Maine: Maine Bureau of Helth; 1996. [Google Scholar]
  • 99.Case P, Beckett GA, Jones TS. Access to sterile syringes in Maine: pharmacy practice after the 1993 repeal of the syringe prescription law. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S94–S101. doi: 10.1097/00042560-199802001-00017. [DOI] [PubMed] [Google Scholar]
  • 100.Gleghorn AA, Gee G, Vlahov D. Pharmacists attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S89–S93. doi: 10.1097/00042560-199802001-00016. [DOI] [PubMed] [Google Scholar]
  • 101.Sheridan J, Strang J, Taylor C, Barber N. HIV prevention and drug treatment services for drug misusers: a national study of community pharmacists' attitudes and their involvement in service specific training. Addiction. 1997;92:1737–1748. doi: 10.1111/j.1360-0443.1997.tb02894.x. [DOI] [PubMed] [Google Scholar]
  • 102.Groseclose SL, Weinstein B, Jones TS, Valleroy LA, Fehrs LJ, Kassler WJ. Impact of increased legal access to needles and syringes on parctices of injecting-drug users and police officers—Connecticut, 1992–1993. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:82–89. [PubMed] [Google Scholar]
  • 103.Grund JP, Heckathorn DD, Broadhead RS, Anthony DL. In eastern Connecticut, IDUs purchase syringes from pharmacies but don't carry syringes. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:73–81. doi: 10.1097/00042560-199509000-00016. [DOI] [PubMed] [Google Scholar]
  • 104.Wright-DeAguero L, Weinstein B, Jones ST. Impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers' practices. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S102–S110. doi: 10.1097/00042560-199802001-00018. [DOI] [PubMed] [Google Scholar]
  • 105.Weinstein B, Toce P, Katz D, Ryan LL. Peer education of pharmacists and supplying pharmacies with IDU packets to increase injection drug users' access to sterile syringes in Connecticut. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S146–S147. doi: 10.1097/00042560-199802001-00029. [DOI] [PubMed] [Google Scholar]
  • 106.Junge B, Vlahov D, Riley E, Huettner S, Brown M, Beilenson P. Pharmacy access to sterile syringes for injection drug users: attitudes of participants in a syringe exchange program. J Am Pharm Assoc. 1999;39:17–22. doi: 10.1016/s1086-5802(16)30410-7. [DOI] [PubMed] [Google Scholar]
  • 107.Shah SM, Shapshak P, Rivers JF, et al. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary report. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:301–306. doi: 10.1097/00042560-199603010-00010. [DOI] [PubMed] [Google Scholar]
  • 108.McCoy CB, Metsch LR, Chitwood DD. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton and water. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S25–S29. doi: 10.1097/00042560-199802001-00006. [DOI] [PubMed] [Google Scholar]
  • 109.Henry J. Kaiser. Family Foundation. Menlo Park, CA: Henry J. Kaiser Family Foundation; 1996. [Google Scholar]
  • 110.Keyl PM, Gruskin L, Casano K, Montag H, Junge B, Vlahov D. Community support for needle exchange programs and pharmacy sale of syringes: a household survey in Baltimore, Maryland. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S82–S88. doi: 10.1097/00042560-199802001-00015. [DOI] [PubMed] [Google Scholar]
  • 111.Doherty MC, Garfein RS, Vlahov D, et al. Discarded needles do not increase soon after the opening of a needle exchange program. Am J Epidemiol. 1997;145:730–737. doi: 10.1093/aje/145.8.730. [DOI] [PubMed] [Google Scholar]
  • 112.Oliver KJ, Friedman SR, Maynard H, Magnuson L, Jarlais DC. Impact of a needle exchange program on potentially infectious syringes in public places. J Acquir Immune Defic Syndr Hum Retrovirol. 1992;5:534–535. doi: 10.1097/00126334-199205000-00021. [DOI] [PubMed] [Google Scholar]
  • 113.Doherty M, Junge B, Rathouz P, Riley E, Vlahov D. The effect of needle exchange program on numbers of discarded needles. Am J Public Health. 2000;90(6):936–939. doi: 10.2105/ajph.90.6.936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Macalino GE, Springer KW, Rahman ZS, Vlahov D, Jones TS. Community-based programs for safe disposal of used needles and syringes. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S111–S119. doi: 10.1097/00042560-199802001-00019. [DOI] [PubMed] [Google Scholar]
  • 115.Riley E, Beilenson P, Vlahov D. Operation red box: a pilot project of needle and syringe drop boxes for injection drug users in East Baltimore. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S120–S125. doi: 10.1097/00042560-199802001-00020. [DOI] [PubMed] [Google Scholar]
  • 116.Vlahov D. Deregulation of the sale and possession of syringes for HIV prevention among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:71–72. [PubMed] [Google Scholar]
  • 117.Burris S, Lurie P, Abrahamson D, Rich JD. Physician prescribing of sterile injection equipment to prevent HIV infection: time for action.Ann Intern Med. In press. [DOI] [PubMed]
  • 118.Rich J. Proceedings of Syringe Availability: Exchange, Distribution, Sale or Prescription; 1999 Jun 23; New York. New York: The Lindesmith Center; 1999. Syringe availability: exchange, distribution, sale or prescription. [Google Scholar]
  • 119.Bless R, et al. Urban Policies in Europe 1993. Amsterdam, The Netherlands: Amsterdam: Bureau of Social Research and Statistics; 1993. [Google Scholar]
  • 120.Anonymous. Syringe exchanges by automat.Int J Drug Policy. 1989;1:6.
  • 121.Obadia Y, Feroni I, Perrin V, Vlahov D, Moatti JP. Syringe vending machines for injection drug users: an experiment in Marseille, France. Am J Public Health. 1999;89:1852–1854. doi: 10.2105/ajph.89.12.1852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Dodding J, Gaughwin M. The syringe in the machine. Aust J Public Health. 1995;19:406–409. doi: 10.1111/j.1753-6405.1995.tb00395.x. [DOI] [PubMed] [Google Scholar]
  • 123.Grove D. Negotiation: basing syringe distribution on actual need. In: Proceedings of the Annual North American Syringe Exchange Conference; April 1996; Milwaukee, WI.
  • 124.Caulkins JP, Kaplan EH, Ahn SH. Can difficult-to-reuse syringes reduce the spread of HIV among injection drug users? Operations Res. 1998;28:23–33. [Google Scholar]
  • 125.US Congress, Office of Technology Assessment.Difficult-to-Reuse Needles for the Prevention of HIV Infection Among Injecting Drug Users. Background Paper. Washington, DC: US Government Printing Office; 1992. Report OTA-BP-H-103.
  • 126.Jarlais DC. “Single-use” needles and syringes for the prevention of HIV infection among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S52–S56. doi: 10.1097/00042560-199802001-00010. [DOI] [PubMed] [Google Scholar]
  • 127.Gleghorn AA, Wright-deAgüero L, Flynn C. Feasibility of one-time use of sterile syringes: a study of active injection drug users in seven United States metropolitan areas. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(supp 1):S30–S36. doi: 10.1097/00042560-199802001-00007. [DOI] [PubMed] [Google Scholar]
  • 128.Lurie P, Gorsky R, Jones TS, Shomphe L. An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S126–S132. doi: 10.1097/00042560-199802001-00021. [DOI] [PubMed] [Google Scholar]
  • 129.Holmberg S. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642–654. doi: 10.2105/ajph.86.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Jarlais DC, Marmor M, Friedman P, et al. HIV incidence among injection drug users in New York City, 1992–1997: evidence for a declining epidemic. Am J Public Health. 2000;90:352–359. doi: 10.2105/ajph.90.3.352. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES